|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
48
|
|
pubmed:dateCreated |
2010-11-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Preventive immunization with whole inactivated Mycobacterium vaccae (MV) confers protection against HIV-associated tuberculosis (TB) in BCG-immunized adults with CD4 counts ?200 cells/?l. We evaluated the immunogenicity of MV in the 2013 subjects of the phase III DarDarTrial using an interferon gamma (IFN-?) enzyme linked immunosorbent assay (ELISA), tritiated thymidine lymphocyte proliferation assay (LPA) and an ELISA for antibodies to the TB glycolipid lipoarabinomannan (LAM). MV immunization boosts IFN-? and LPA responses to MV sonicate, and antibody responses to LAM. Post-immunization immune responses to MV correlated with baseline clinical factors, but the responses did not predict protection from HIV-associated TB.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Antitubercular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/BCG Vaccine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Isoniazid,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Tuberculosis Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/lipoarabinomannan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1873-2518
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7652-8
|
|
pubmed:dateRevised |
2011-11-10
|
|
pubmed:meshHeading |
pubmed-meshheading:20875492-Adult,
pubmed-meshheading:20875492-Antibodies, Bacterial,
pubmed-meshheading:20875492-Antibody Formation,
pubmed-meshheading:20875492-Antigens, Bacterial,
pubmed-meshheading:20875492-Antitubercular Agents,
pubmed-meshheading:20875492-BCG Vaccine,
pubmed-meshheading:20875492-Double-Blind Method,
pubmed-meshheading:20875492-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20875492-Female,
pubmed-meshheading:20875492-HIV Infections,
pubmed-meshheading:20875492-Humans,
pubmed-meshheading:20875492-Interferon-gamma,
pubmed-meshheading:20875492-Isoniazid,
pubmed-meshheading:20875492-Lipopolysaccharides,
pubmed-meshheading:20875492-Male,
pubmed-meshheading:20875492-Tanzania,
pubmed-meshheading:20875492-Tuberculin Test,
pubmed-meshheading:20875492-Tuberculosis,
pubmed-meshheading:20875492-Tuberculosis Vaccines,
pubmed-meshheading:20875492-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.
|
|
pubmed:affiliation |
Dartmouth Medical School, Lebanon, NH 03756,USA. Timothy.Lahey@Dartmouth.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
